Publication: Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count
Issued Date
2007-06-01
Resource Type
ISSN
0125877X
Other identifier(s)
2-s2.0-36048951337
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Allergy and Immunology. Vol.25, No.2-3 (2007), 147-154
Suggested Citation
Somsit Tansuphaswadikul, Saw Eindani Aung, Benjaluck Phonrat, Jaranit Kaewkungwal, Punnee Pitisuttithum, Wirach Maek-a-nantawat Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count. Asian Pacific Journal of Allergy and Immunology. Vol.25, No.2-3 (2007), 147-154. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/24548
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count
Other Contributor(s)
Abstract
The objective of the study was to determine the predisposing factors and incidence of toxicity among AIDS patients treated with a nevirapine (NVP)-based regimen in clinical practice. A retrospective cohort study of representative samples of AIDS patients treated with a NVP-based regimen was performed. A total of 206 adult HIV/AIDS cases with median age (IQR) 33 years (range, 29-38 years), 51% male, treated between January 2004-December 2005, were included. Most (92.2%) of the patients were naïve to antiretroviral drug. The incidence of NVP toxicity was 1.09/100 person-months. The median onset time was 4 weeks post NVP initiation (2.57 weeks for skin toxicity and 12.43 weeks for hepatic toxicity). History of drug allergy and NVP toxicity were significantly associated (p = 0.006), as were sulfamethoxazole allergy and toxicity (p = 0.015). Regarding concomitant medication, concurrent anti-tuberculosis drugs significantly increased the risk of NVP associated liver toxicity (p = 0.001). Therefore, it is important to monitor adverse events from NVP, including liver function tests among HIV/AIDS patients with history of drug allergy, especially against sulfamethoxazole, and those concurrently treated with anti-tuberculosis drugs.